- Pharmascience Canada has launched pms–Dolutegravir (dolutegravir tablets) in Canada, expanding its portfolio in the HIV treatment space
- The company is the only Canadian generic manufacturer to receive authorization from Health Canada for this product
- Dolutegravir is a widely used antiretroviral therapy for HIV, forming a key part of modern treatment regimens
- The launch aims to improve patient access and support a more sustainable healthcare system by offering a high-quality, affordable generic option
Takeaways:
Pharmascience Canada has launched pms–Dolutegravir, becoming the only Canadian generic manufacturer with Health Canada authorization for dolutegravir tablets and adding a key HIV backbone to its growing antiretroviral portfolio.
Because dolutegravir anchors many first‑line and switch regimens, a domestically made, lower‑cost generic should ease drug‑plan budgets and improve long‑term treatment access, supporting a more sustainable HIV care ecosystem while reinforcing Pharmascience’s positioning as a go‑to Canadian supplier for complex generics.
Source: CA Newswire
